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Abstract
We have recently reported that the homologous Rho kinases, ROCK1 and ROCK2, play different roles in regulating stress-
induced stress fiber disassembly and cell detachment, and the ROCK1 deficiency in mouse embryonic fibroblasts (MEF) has
remarkable anti-apoptotic, anti-detachment and pro-survival effects against doxorubicin, a chemotherapeutic drug. This
study investigated the roles of ROCK isoforms in doxorubicin-induced reactive oxygen species (ROS) generation which is
believed to be the major mechanism underlying its cytotoxicity to normal cells, and especially to cardiomyocytes. Different
antioxidants have been shown to provide a protective role reported in numerous experimental studies, but clinical trials of
antioxidant therapy showed insufficient benefit against the cardiac side effect. We found that both ROCK12/2 and ROCK22/
2 MEFs exhibited reduced ROS production in response to doxorubicin treatment. Interestingly, only ROCK1 deficiency, but
not ROCK2 deficiency, significantly enhanced the protective effects of antioxidants against doxorubicin-induced
cytotoxicity. First, ROCK1 deficiency and N-acetylcysteine (an anti-oxidant) treatment synergistically reduced ROS levels,
caspase activation and cell detachment. In addition, the reduction of ROS generation in ROCK12/2 MEFs in response to
doxorubicin treatment was in part through inhibiting NADPH oxidase activity. Furthermore, ROCK1 deficiency enhanced the
inhibitory effects of diphenyleneiodonium (an inhibitor of NADPH oxidase) on ROS generation and caspase 3 activation
induced by doxorubicin. Finally, ROCK1 deficiency had greater protective effects than antioxidant treatment, especially on
reducing actin cytoskeleton remodeling. ROCK1 deficiency not only reduced actomyosin contraction but also preserved
central stress fiber stability, whereas antioxidant treatment only reduced actomyosin contraction without preserving central
stress fibers. These results reveal a novel strategy to enhance the protective effect of antioxidant therapy by targeting the
ROCK1 pathway to stabilize the actin cytoskeleton and boost the inhibitory effects on ROS production, apoptosis and cell
detachment.
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Introduction
The ROCK family contains two members: ROCK1 and
ROCK2, which share 92% identity in the kinase domain [1–3].
ROCK plays a critical role in mediating the effects of small
GTPase RhoA on stress fiber formation, smooth muscle contrac-
tion, cell adhesion, and cell motility [4,5]. The best characterized
targets of ROCK in the vascular system are myosin light chain
(MLC) phosphatase (MYPT), MLC [6–8], and LIM-kinases
(LIMK) [9,10]. These ROCK-mediated pathways are known to
be involved in stress fiber assembly and cell adhesion. Using mouse
embryonic fibroblasts (MEFs) derived from ROCK12/2 and
ROCK22/2 mice, we recently demonstrated that ROCK1 and
ROCK2 can differently regulate stress fiber disassembly and cell
adhesion under stress conditions such as cytotoxicity induced by
doxorubicin, a chemotherapeutic agent used to treat a wide
spectrum of hematologic malignancies and solid tumors for
decades, or serum starvation, a frequently used environmental
stress in cell biology [11,12]. We demonstrated that ROCK2 is
required for stabilizing the actin cytoskeleton through regulating
cofilin phosphorylation under stress conditions, and in contrast,
ROCK1 is involved in destabilizing the actin cytoskeleton through
regulating MLC phosphorylation and peripheral actomyosin
contraction [11,12]. These findings support a novel concept that
ROCK1 and ROCK2 can differently regulate stress fiber
disassembly, cell adhesion and cell death under stress conditions.
Although doxorubicin has been shown to increase actin
cytoskeleton instability through the inhibition of actin polymeri-
zation [13,14], the excessive generation of free reactive oxygen
species (ROS) in the drug treatment can also be involved in actin
cytoskeleton remodeling and promoting the activation of multiple
signaling mechanisms, resulting in cell damage via apoptosis,
necrosis, autophagy and senescence [15–22]. ROS production is
believed to be the major mechanism underlying its cytotoxicity to
normal cells in most major organs, including heart [20–26]. Many
studies have suggested that antioxidants have a protective effect on
chemotherapy-induced cytotoxicity. However, clinical trials of
antioxidant therapy showed only limited beneficial effects [27,28].
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In this study, we showed that the deletion of either isoforms of
ROCK inhibited ROS production induced by doxorubicin.
Interestingly, only ROCK1 deficiency, but not ROCK2 deficien-
cy, significantly enhanced the protective effects of antioxidants
against doxorubicin-induced cytotoxicity. We also showed that the
reduction of ROS generation in ROCK12/2 MEFs under
doxorubicin treatment was in part through inhibiting NADPH
oxidase activity. ROCK1 deficiency and N-acetylcysteine (NAC,
an anti-oxidant) treatment synergistically reduced ROS levels,
caspase activation and cell detachment. We further showed that
ROCK1 deficiency enhanced the inhibitory effects of diphenyle-
neiodonium (DPI, an inhibitor of NADPH oxidase) on ROS
generation and caspase 3 activation. Importantly, ROCK1
deficiency had greater effects than antioxidant treatment in
reducing actin cytoskeleton remodeling. Our results suggest that
the greater anti-remodeling effects of ROCK1 deficiency are
mediated through reducing actomyosin contraction and preserv-
ing central stress fiber stability; NAC treatment, though it also
decreases actomyosin contraction, does not stabilize central stress
fibers, therefore providing less protection to actin cytoskeleton
structure. These results reveal a novel strategy to improve
antioxidant therapeutic efficacy by adding a ROCK isoform
specific inhibitor to target the ROCK1 pathway. Their synergistic
effects may further extend the protection against oxidative stress
through stabilizing the actin cytoskeleton, decreasing ROS
overproduction and apoptosis, improving cell adhesion as well as
alleviating tissue remodeling.
Results
ROCK1 Deletion Reduces Doxorubicin-induced ROS
Production
Free radical generation and oxidative stress occur soon after
starting doxorubicin treatment and significantly contribute to the
drug’s cytotoxic effects. Our previous studies revealed that the
deletion of ROCK1 in MEFs inhibits apoptosis and cell
detachment [11,12]. To determine if the protective effects of
ROCK1 deficiency contributes to the reduced ROS, we measured
intracellular ROS generation with the chloromethyl derivative of
dichlorodihydrofluorescein diacetate (CM-H2DCFDA), an oxi-
dant-sensitive dye (Fig. 1). As expected, fluorescence microscopy
analysis revealed that ROS levels increased by 3.97 folds in WT
MEFs in response to 3 mM of doxorubicin treatment for 4 h
(Fig. 1A–B). Interestingly, ROS generation was markedly reduced
in ROCK1 deficient MEFs (2.08-fold increase, Fig. 1A–B). The
doxorubicin-induced ROS overproduction was also observed by
flow cytometry in WT MEFs in a dose-dependent manner
(Fig. 1C–D). This dose-dependent increase of ROS was signifi-
cantly reduced in ROCK1 deficient MEFs (Fig. 1C–D). These
results suggest that the inhibition of intracellular ROS by ROCK1
deletion contributes, at least in part, to its cytoprotective effects.
ROCK1 Deletion Enhances Anti-ROS, Pro-survival, Anti-
apoptotic Effects of the Anti-oxidant NAC
NAC has multiple clinical applications attributed to its ability to
support the body’s antioxidant and nitric oxide systems during
stress, infections, toxic assault, and inflammatory conditions due to
its fast reactions with free radicals [29,30]. In addition, it protects
animals against doxorubicin-induced cardiotoxicity [31]. As
expected, the treatment of WT MEFs with 2 mM of NAC
inhibited doxorubicin-induced ROS production measured by flow
cytometry (Fig. 2A). In addition, the improved viability revealed
by MTT assay (Fig. 2B) and reduced doxorubicin-induced caspase
activation (Fig. 2C–D) were also observed in NAC treated WT
MEFs. It is worth noting that the protective effect of 2 mM of
NAC was less effective than the effect of ROCK1 deletion
(Fig. 2A–D). Besides the treatment with 2 mM of NAC and 3 mM
of doxorubicin for 16 h, which was used for most of the
experiments presented in this study, we have also analyzed the
cells with different drug concentrations, for example, different
NAC concentrations ranging from 1 to 10 mM, doxorubicin
concentrations varying from 1 to 5 mM, and time points changing
from 4 to 24 h. We found that under all tested conditions, the anti-
ROS and anti-apoptotic effects of NAC treatment were less
effective than those from ROCK1 deletion (data not shown).
Moreover, synergistic effects of NAC treatment and ROCK1
deletion were evidenced by the further reduction of doxorubicin-
induced ROS production (Fig. 2A) and caspase activation
(Fig. 2C–D) in NAC treated ROCK1 deficient MEFs. A trend
of an increase in cell viability was also observed in NAC treated
ROCK1 deficient MEFs, but the difference was not statistically
significant (Fig. 2B). Therefore, NAC treatment together with
ROCK1 deletion was more effective than NAC treatment or
ROCK1 deletion alone on reducing ROS production and
suppressing caspase activation.
ROCK1 Deletion Reduces Doxorubicin Induced Actin
Cytoskeleton Remodeling to a Greater Degree than
Antioxidant NAC
Our previous study [11,12] revealed that doxorubicin induces
actin cytoskeleton remodeling which is characterized by the
formation of a cortical contractile ring at the cell periphery
accompanied by the disruption of central stress fibers as shown in
Fig. 3A. It induces an increase in MLC phosphorylation, which
mediated by both ROCK1 and ROCK2, and contributes to the
increased actomyosin contraction; it also induces an increase in
cofilin phosphorylation which mainly mediated by ROCK2,
promotes actin polymerization and stress fiber stability [11,12].
To evaluate the effects of NAC treatment on actin cytoskeleton
remodeling, we examined actin cytoskeleton changes after
doxorubicin treatment in the presence and absence of NAC.
Phalloidin staining revealed that the NAC treatment did not
prevent doxorubicin-induced disruption of central stress fibers
(Fig. 3A) and had an inhibitory effect on doxorubicin-induced
cofilin phosphorylation (Fig. 3B–C). However, NAC treatment
also had inhibitory effects on doxorubicin-induced MLC phos-
phorylation (Fig. 3B–C). Our previous study using blebbistatin, a
direct inhibitor of myosin II ATPase, revealed that doxorubicin-
induced actomyosin contraction contributes to cell detachment
[11]. Consistent with reduced MLC phosphorylation, NAC
treatment decreased doxorubicin-induced cell detachment
(Fig. 3D–E). Compared to NAC treatment, ROCK1 deletion
was more effective on reducing actin cytoskeleton remodeling and
cell detachment induced by doxorubicin (Fig. 3A–E). ROCK1
deletion not only reduced doxorubicin-induced MLC phosphor-
ylation but also preserved cofilin phosphorylation (Fig. 3B–C) as
previously observed [11,12]. Similar to the anti-ROS and anti-
apoptotic effects described above, NAC treatments at the
concentrations ranging from 1 to 10 mM were all less effective
than ROCK1 deletion on reducing doxorubicin-induced cell
detachment (data not shown). The NAC treatment in ROCK1
deficient MEFs showed a trend of further inhibiting cell
detachment, but the difference was not statistically significant
(Fig. 3D–E). Consistent with preserved actin cytoskeleton stability
in ROCK1 deficient MEFs, co-treatment of doxorubicin with
NAC had no detectable effects on MLC and cofilin phosphory-
lation in these cells (Fig. 3B). These results support the superior
ability of ROCK1 deletion in preserving actin cytoskeleton
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stability, which underlies the synergistic effects of ROCK1
deletion and antioxidant treatment against doxorubicin-induced
cytotoxicity.
ROCK1 Deletion Reduces NADPH Oxidase Activation
Induced by Doxorubicin
NADPH oxidases have been identified as important sources of
doxorubicin-induced ROS production [32,33]. The prototypic
NADPH oxidase comprises a catalytic core (Nox2/p22phox) and
several cytosolic subunits (p47phox, p67phox, p40phox, Rac),
which associate together upon activation [34]. Since ROCK1
deletion alone or allied with NAC inhibited doxorubicin-induced
ROS production (Fig. 1), we asked if ROCK1 deficiency affects
NADPH oxidase activity. We measured NADPH oxidase activity
in WT and ROCK12/2 MEFs before and after doxorubicin
treatment (Fig. 4A). The results indicated that doxorubicin
treatment increased NADPH oxidase activity in WT MEFs, but
this drug-induced NADPH oxidase activity was markedly reduced
in ROCK1 deficient MEFs (Fig. 4A). Rac1 is known as an
important subunit of NADPH oxidase and its activation is essential
for the oxidase activity [35,36]. To examine if Rac1 activation is
involved in doxorubicin-induced cytotoxicity, we measured Rac1
activity through affinity precipitation of active Rac1 (Rac1-GTP)
using GST fusion-protein containing the p21-binding domain
(PBD) of Rac1 effector, p21-activated protein kinase (PAK)-1,
followed by Western blot analysis. The results indicate that
doxorubicin treatment increased Rac1 activity which is consistent
to the increased NADPH oxidase activity in WT MEFs, but the
activity was markedly reduced in ROCK1 deficient MEFs
(Fig. 4B). Coinciding with doxorubicin-elevated NADPH oxidase
and Rac1 activations, membrane translocations of both p67phox
and Rac1 were found increased in WT MEFs, but were
significantly reduced in ROCK1 deficient MEFs (Fig. 4C).
ROCK1 Deletion Enhances the Anti-ROS and Anti-
apoptotic Effects of NADPH Oxidase Inhibitor DPI
We subsequently examined the contribution of NADPH oxidase
activity to doxorubicin-induced ROS generation and caspase
activation using DPI, a chemical inhibitor. DPI treatment at 1 mM
reduced doxorubicin-induced ROS generation in WT cells as well
as in ROCK1 deficient cells (Fig. 5A–B). In addition, DPI
treatment attenuated caspase activation in WT MEFs (Fig. 5C–D)
and further reduced caspase activation in ROCK1 deficient
MEFs, supporting synergistic protective effects of DPI and
ROCK1 deletion. Moreover, increasing concentrations of DPI
to 5–10 mM did not improve its anti-ROS and anti-apoptotic
effects, but instead, showed increased cytotoxic effects with
reduced cell viability (data not shown). Similar to the NAC
treatment described above, under all tested conditions with
different doses and time points, the protective effect of ROCK1
deletion was more effective than that of DPI (data not shown).
ROCK1 Deletion Preserves Central Stress Fibers in DPI
and Doxorubicin Treated Cells
To examine the effects of DPI on doxorubicin-induced actin
cytoskeleton remodeling, we performed phalloidin staining in WT
and ROCK12/2 MEFs. We observed that DPI treatment alone
induced the disruption of central stress fibers in WT MEFs
(Fig. 6A). Although the mechanisms underlying this disruptive
effect of DPI on the actin cytoskeleton are not clear, ROCK12/2
Figure 1. ROCK1 deletion reduces doxorubicin-induced ROS production. A. Representative images of CM-H2DCFDA staining. WT and
ROCK12/2 MEFs were grown on glass coverslips, treated for 4 h with 3 mM doxorubicin and then exposed to 13 mM CM-H2DCFDA. Coverslip was
mounted with Vector mounting medium containing DAPI and imaged immediately. Bar, 50 mm. B. Quantitative analysis of the images obtained from
fluorescence microscopy with the Leica AF6000 software. Fluorescence levels in WT cells at baseline were arbitrarily set at 1. C and D. Representative
results (C) and quantitative analysis (D) of ROS measured by flow cytometry analysis after staining with CM-H2DCFDA. WT and ROCK12/2 cells were
treated for 16 h with 3 mM doxorubicin (C) or with the dosages of doxorubicin as indicated (D). The attached cells were stained with 5 mM CM-
H2DCFDA, collected and analyzed by flow cytometry in at least three separate experiments. Fluorescence levels in WT cells at baseline were arbitrarily
set at 1. *P,0.05 vs. control of the same genotype. #P,0.05 vs. WT under the same treatment condition.
doi:10.1371/journal.pone.0090758.g001
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MEFs were resistant to this cytotoxic effect with preserved central
stress fibers (Fig. 6A). Our previous study using cytochalasin D, an
inhibitor of actin polymerization, indicated that the disruption of
central stress fibers exaggerates doxorubicin-induced cell detach-
ment [11]. Consistent with the apparent disruptive effects of DPI
on the stress fibers in WT MEFs but not in ROCK12/2 MEFs
(Fig. 6A), the co-treatment with DPI further worsened doxorubi-
cin-induced cell detachment in WT MEFs but not in ROCK12/2
MEFs (Fig. 6B–C). Although ROCK12/2 MEFs were resistant to
the disruptive effects of DPI on stress fibers, DPI treatment alone
was able to cause a slight but significant increase in cell
detachment (Fig. 6B–C), suggesting that DPI has multiple
cytotoxic effects. Together, these results further support the
concept that ROCK1 deletion is highly effective in inhibiting
actin cytoskeleton remodeling induced by various cytotoxic
stresses.
ROCK2 Deletion does not Enhance Protective Effects of
Antioxidants
To examine the impact of ROCK2 deletion on the protective
effects of antioxidants, we assessed the effects of NAC or DPI on
doxorubicin-induced cytotoxicity in ROCK22/2 MEFs. Similar to
ROCK12/2MEFs, ROCK22/2MEFs also exhibited reduced ROS
production in doxorubicin treatment (Fig. 7A–B), which was
accompanied by reduced caspase activation (Fig. 7C–D). Howev-
er, NAC treatment of ROCK22/2 MEFs had no additional anti-
ROS and anti-apoptotic effects (data not shown). Resembling the
finding in WT MEFs, NAC or DPI treatment in ROCK22/2
MEFs was not able to attenuate doxorubicin-induced disruption of
central stress fibers (Fig. 8A). Moreover, DPI treatment alone
increased peripheral membrane folding in ROCK22/2 MEFs
(Fig. 8A), consistent with our previous observations that ROCK2
deletion in MEFs leads to increased actin cytoskeleton instability
and impaired cell adhesion [11,12]. In accordance with cell
adhesion impairment, ROCK22/2 MEFs showed a trend toward
increasing cell detachment compared to the WT MEFs after
doxorubicin, with or without the co-treatment of NAC (Fig. 8B) or
DPI (Fig. 8C). Besides, we did not find any additional effect of DPI
treatment on decreasing caspase activation in ROCK22/2 MEFs
(Fig. 8D–E). Together these results indicate that ROCK2 deletion,
in contrast to ROCK1 deletion, does not enhance the cytopro-
tective effects of antioxidants, likely due to its deleterious effect on
actin cytoskeleton stability.
Discussion
The present study used MEFs derived from ROCK12/2 and
ROCK22/2 mice to investigate the role of ROCK isoforms in
regulating ROS production and compare the effects of the genetic
approach in combination with chemical antioxidant treatments on
reducing doxorubicin-induced cytotoxicity. We found that both
ROCK12/2 and ROCK22/2 MEFs exhibited reduced ROS
production in response to doxorubicin treatment, but interestingly,
only ROCK1 deficiency showed greater protection than antiox-
idant NAC including anti-ROS production, anti-apoptotic and
anti-detachment effects. In addition, only ROCK1 deficiency
showed synergistic protective effects when combined with NAC.
Further examinations showed that ROCK12/2 MEFs exhibited
Figure 2. ROCK1 deletion enhances anti-ROS, pro-survival, anti-apoptotic effects of NAC. A. ROS levels measured by flow cytometry
analysis after CM-H2DCFDA staining of attached WT and ROCK12/2 MEFs after 3 mM doxorubicin and/or 2 mM NAC treatment for 16 h; showing a
minimal doxorubicin-induced ROS production in NAC treated ROCK1 deficient MEFs. Fluorescence levels in WT cells at baseline were arbitrarily set at
1. B. MTT assay performed with MEFs treated for 16 h with 3 mM doxorubicin and/or 2 mM NAC showing maximal level of cell viability after
doxorubicin treatment in NAC treated ROCK1 deficient MEFs. C. Representative image of Western blot of cleaved caspase-3 and -8 in cell lysates from
attached WT and ROCK1 deficient MEFs treated with 3 mM doxorubicin and/or 2 mM NAC for 16 h. Equal amount of proteins were loaded. D.
Densitometry analysis of immunoreactive bands of cleaved caspase-3 expressed as percent change relative to WT cells treated with 3 mM
doxorubicin, showing a minimal level of caspase activation in NAC treated ROCK1 deficient MEFs. *P,0.05 vs. control of the same genotype. #P,0.05
vs. WT under the same treatment condition. "P,0.05 vs. the same genotype under doxorubicin only condition.
doi:10.1371/journal.pone.0090758.g002
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Figure 3. ROCK1 deletion enhances anti-detachment effects of NAC. A. Representative images of rhodamine-phalloidin staining for F- actin
(red), p-MLC staining (green) and DAPI (blue) of WT and ROCK1 deficient cells treated with 3 mM doxorubicin and/or 2 mM NAC for 8 h. Cells showing
disruption of central stress fibers are indicated with white arrowheads. ROCK1 deletion, but not NAC treatment, prevents DOX-induced disruption of
central stress fibers. Bar, 25 mm. B and C. Representative image (B) of Western blot of p-MLC2 and MLC2, or p-cofilin and cofilin in cell lysates from
attached WT and ROCK12/2 MEFs treated with 3 mM doxorubicin and/or 2 mM NAC for 30 min. Quantitative analysis (C) showing reduction of both
p-MLC and p-cofilin in WT MEFs after NAC/DOX treatment compared to DOX treatment alone. The ratio of p-MLC to MLC or p-cofilin to cofilin was
ROCK Isoform Function in Oxidative Stress Response
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reduced NADPH oxidase activation in doxorubicin treatment,
which likely contributed to the diminished ROS. Moreover,
ROCK1 deficiency not only enhanced the inhibitory effects of
DPI on ROS generation and caspase 3 activation, but also
attenuated cell detachment caused by DPI. The superior
protective effects of ROCK1 deficiency over NAC, DPI
treatments or ROCK2 deficiency were associated with the
preservation of central stress fibers in response to doxorubicin,
which was only observed in ROCK12/2 MEFs. These results
support the concept that increased actin stability from ROCK1
deficiency sustains the protective effects of antioxidants, revealing
a novel strategy to enhance cytoprotective effects of antioxidant
treatments against cytotoxicity induced by doxorubicin which
possibly can be extended to other oxidative stresses.
Many studies have suggested a chemo-protecting role for
antioxidants [27,28]. Nevertheless, various antioxidants allied with
doxorubicin in clinical trials showed very limited beneficial effects
against doxorubicin-induced cardiotoxicity and the cytotoxicity to
other major organs [27,28]. The present study provides a potential
explanation for this below-expected outcome as antioxidants may
have limited effects on cytoskeleton remodeling. Our results
showed that although NAC or DPI treatment decreased ROS
production and caspase activation induced by doxorubicin, NAC
had no protective effect against the disruption of stress fibers,
whereas DPI even increased the disruption of stress fibers.
Although NAC treatment reduced MLC phosphorylation and
actomyosin contraction, it also decreased cofilin phosphorylation
leading to increased actin depolymerization. These inhibitory
effects of NAC on both MLC and cofilin phosphorylation were
previously observed in ROCK2 deficient cells, but not in ROCK1
deficient cells, in which only MLC phosphorylation but not cofilin
phosphorylation was reduced. The simultaneous inhibition of
MLC and cofilin phosphorylation by NAC is consistent with
previous reports that antioxidant treatments reduce RhoA/
ROCK activation [37,38], which likely involve both ROCK1
and ROCK2. Together with our previous observations that
ROCK1 deletion preserves actin cytoskeleton stability in response
to doxorubicin or serum starvation [11,12], the present study by
combining NAC or DPI with doxorubicin further support the
concept that ROCK1 deletion is highly effective in inhibiting actin
cytoskeleton remodeling induced by cytotoxic stresses through
preferentially inhibiting the cytotoxic pathway mediated by
increased actomyosin contraction while preserving the cytopro-
tective pathway mediated by cofilin phosphorylation. It is worth
expressed as fold change relative to WT control. D and E. Both floating and attached cells were collected after treatment for 16 h with 3 mM
doxorubicin and/or 2 mM NAC. Floating cell ratio was expressed as percentage of total cells (floating plus attached cells) under each treatment
condition (D). Attached cell number was expressed as percentage of attached cells under control condition without treatment (E). *P,0.05 vs. control
of the same genotype. #P,0.05 vs. WT under the same treatment condition. "P,0.05 vs. the same genotype under doxorubicin only condition.
doi:10.1371/journal.pone.0090758.g003
Figure 4. ROCK1 deletion reduces NADPH oxidase and Rac1 activity and membrane translocation of p67phox and Rac1 in response
to doxorubicin. NADPH oxidase activity assay (A) and Rac1 activity pull-down assay (B) were performed with WT and ROCK12/2 MEFs after
treatment for 16 h with 3 mM doxorubicin showing reduced NADPH oxidase activation in ROCK1 deficient cells. The activity was expressed as fold
change relative to WT control. C. Representative image (top) and quantitative analysis (bottom) of Western blot of p67phox and Rac1 performed with
membrane fractions from attached WT and ROCK12/2 MEFs treated with 3 mM of doxorubicin at indicated time points. *P,0.05 vs. control of the
same genotype. #P,0.05 vs. WT under the same treatment condition.
doi:10.1371/journal.pone.0090758.g004
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noting that the increased cofilin phosphorylation leads to an
increase in F-actin and decreases in G-actin, a process which may
also cause cell function aberrant under some conditions. However,
ROCK1 deletion has no detectable effect on F/G ratio at baseline
condition [12]. Under stress conditions, especially cytotoxic
stresses such as doxorubicin cytotoxicity or serum starvation
[11,12] which affect actin cytoskeleton stability, the increased
cofilin phosphorylation by ROCK1 deletion has a beneficial role
in maintaining F/G ratio and preserving actin cytoskeleton
stability as well cell adhesion.
NADPH oxidase is one of the important ROS sources and is
involved in doxorubicin cytotoxicity [32,33]. We showed in this
study that the inhibition of NADPH oxidase by DPI decreased
ROS levels and caspase activation in doxorubicin treatment. We
have also shown that ROCK1 deficiency reduced NADPH
oxidase activity which was associated with reduced membrane
translocations of p67phox and Rac1, which are key steps in the
assembly of the active enzyme complex. The mechanisms
underlying the inhibition of NADPH oxidase activation by
ROCK1 deletion appears to be related with the reduced activation
of Rac1 observed in the present study. Rac1 is an important
subunit of NADPH oxidase and interacts with p67phox [35,36].
Future studies are needed to investigate the mechanisms impli-
cated in the inhibition of Rac1 activation by ROCK1 deletion and
to explore other potential mechanisms involved in ROCK1-
mediated NADPH oxidase activation in response to doxorubicin
or other cytotoxic drugs. Previous reports have shown that ROCK
was involved in the NADPH oxidase-mediated production of ROS
in endothelial cells, hepatocytes and macrophages [39–41], but the
contribution of each ROCK isoform was not determined.
ROCK1 may be involved in the oxidative stress responses through
modulating NADPH oxidase activity in a wide range of
pathological conditions including inflammation, reperfusion injury
and degeneration etc. It would be of interest to validate the present
finding to other disease in vitromodels and move forward to animal
models of cardiovascular, metabolic and neurodegenerative
diseases in which oxidative stresses play significant pathological
roles.
Future studies are also needed to explore how the increased
actin cytoskeleton stability from ROCK1 deletion enhances the
anti-ROS, anti-apoptotic and anti-detachment effects of antioxi-
dant treatments. Our previous studies have shown that the
increased actin cytoskeleton stability from ROCK1 deletion
promotes cell-cell and cell-matrix adhesion therefore increasing
adhesion-mediated survival signaling and decreasing apoptosis
[11,12]. It remains to be determined whether the increased actin
cytoskeleton stability from ROCK1 deletion results in reduced
cellular energy consumption, and consequently contributes to
reduced ROS production. It is worth noting that other potential
sources of ROS overproduction induced by doxorubicin include
mitochondria- and nitric oxide synthases-dependent ROS pro-
duction [22]. It would be of interest to determine the effects of
ROCK1 deletion on the ROS production from these sources.
Finally, it would also be of interest to determine if combining
ROCK1 deficiency with antioxidants only provides synergistic
protective effects to normal cells, without reducing the tumor cell-
Figure 5. ROCK1 deletion enhances the anti-ROS and anti-apoptotic effects of DPI. A. Representative images of CM-H2DCFDA staining of
WT and ROCK12/2 MEFs treated for 4 h with 3 mM doxorubicin and/or 1 mM DPI. Coverslip was mounted with Vector mounting medium containing
DAPI and imaged immediately by fluorescence microscopy. Bar, 50 mm. B. Quantitative analysis of the images obtained from fluorescence microscopy
with the Leica AF6000 software. Fluorescence level in WT cells under doxorubicin only condition was arbitrarily set at 1. C. Representative image of
Western blot of cleaved caspase-3, -8, and -9 in cell lysates from attached WT and ROCK1 deficient MEFs treated for 16 h with 3 mM doxorubicin and/
or 1 mM DPI. Equal amount of proteins were loaded. D. Densitometry analysis of immunoreactive bands of cleaved caspase-3 expressed as percent
change relative to WT cells treated with 3 mM doxorubicin, showing minimal level of caspase activation in DPI treated ROCK1 deficient MEFs. *P,0.05
vs. control of the same genotype. #P,0.05 vs. WT under the same treatment condition. "P,0.05 vs. the same genotype under doxorubicin only
condition.
doi:10.1371/journal.pone.0090758.g005
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killing ability of anti-tumor drugs including doxorubicin. In this
regard, our recent study indicates that in contrast to normal cells,
ROCK1 deletion reduces survival of oncogene-bearing cells,
which exhibit different cytoskeletal organizations compared to
normal cells [42].
In summary, this study indicates that targeting the ROCK1
pathway significantly enhances the protective effects of antioxidant
treatments against doxorubicin cytotoxicity, providing a novel
strategy for chemoprotection. ROCK1 deficiency improves
antioxidant treatment through multiple mechanisms including
reducing NADPH oxidase activation and ROS production as well
as preserving actin cytoskeleton stability in response to doxorubi-
cin. A model to summarize all of these findings is schemed in Fig. 9.
Future studies in animal models are needed to validate this novel
strategy for chemoprotection against doxorubicin and other
chemotherapeutic drug-induced oxidative stress and toxicity.
During the last decade, the ROCK family has emerged as a
promising therapeutic target in a wide range of human diseases,
including cardiovascular disorders, neurologic disorders, metabolic
disorders, and cancers [43–46]. The currently available ROCK
pan-inhibitors produced beneficial effects in many experimental
and clinical studies, in particular in a mouse model of doxorubicin-
induced chronic cardiotoxicity [47]. However these inhibitors
inhibit both ROCK1 and ROCK2, and destabilize actin
cytoskeleton to a worse degree than the outcome of the ROCK2
deletion [11]; they may not enhance protective effects of
antioxidants against doxorubicin and other oxidative stress-related
cytotoxicity, and may even apply cytotoxic effects. It is worth
noting that the inhibition of ROCK1 deletion on actin cytoskel-
eton remodeling observed in this study is consistent with our
previous in vivo observations that ROCK1 deletion inhibits cardiac
remodeling and cardiomyocyte apoptosis in pathological heart
failure [48–50]. Future studies are needed to determine if ROCK1
deficiency not only reduces aberrant contraction through
decreasing MLC phosphorylation in the vasculature and in the
heart in response to pathological stimulation, but also improves
survival of cardiovascular cells, especially endothelial cells and
cardiomyocytes, through preserving actin cytoskeleton stability in
these cells, which are the major targets of pathological stimuli
including doxorubicin-induced cardiotoxicity. The current obser-
vations therefore support the development of isoform-selective
ROCK1 inhibitors.
Materials and Methods
Cell Culture and Treatments
ROCK1- or ROCK2-deficient MEF cells were prepared from
ROCK12/2 or ROCK22/2 embryos as previously described [11].
All animal experiments were conducted in accordance with the
National Institutes of Health ‘‘Guide for the Care and Use of
Laboratory Animals’’ (NIH Publication No. 85-23, revised 1996)
and were approved by the Institutional Animal Care and Use
Figure 6. ROCK1 deletion preserves central stress fibers in DPI and doxorubicin treated cells. A. Representative images of rhodamine-
phalloidin staining for F-actin (red) and DAPI staining (blue) of WT and ROCK12/2 cells treated with 3 mM doxorubicin and/or 1 mM DPI for 16 h. Cells
showing disruption of central stress fibers are indicated with white arrowheads. DPI treatment alone induces disruption of central stress fibers in WT
cells. ROCK1 deletion prevents doxorubicin and/or DPI-induced disruption of central stress fibers. Bar, 25 mm. B and C. DPI increases doxorubicin-
induced cell detachment in WT MEFs but not in ROCK1 deficient MEFs. Floating cells (B) and attached cells (C) were collected at 16 h post-treatment
with 3 mM doxorubicin and/or 1 mM DPI. Floating cell ratio was expressed as percentage of total cells (floating plus attached cells) under each
treatment condition. Attached cell number was expressed as percentage of attached cells under control condition without treatment. *P,0.05 vs.
control of the same genotype. #P,0.05 vs. WT under the same treatment condition. "P,0.05 vs. the same genotype under doxorubicin only
condition.
doi:10.1371/journal.pone.0090758.g006
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Committee at Indiana University School of Medicine. Cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM; Life
Technologies) supplemented with 10% fetal bovine serum (FBS;
Atlanta Biologicals) and penicillin-streptomycin in a humidified
incubator with 5% CO2 at 37uC. Cells at 80–90% confluency
were treated with various drugs at indicated times and dosages.
These drugs include doxorubicin, NAC and DPI (Sigma).
Cell Viability and Detachment Assays
For cell viability assay, following the treatment with desired
drugs at indicated concentrations and time points, methylthiazole
tetrazolium (MTT) assay was performed as previously described
[11]. At least three independent experiments were analyzed. For
the cell detachment assay, cells were cultured in DMEM
supplemented with 10% FBS to reach 90% confluency, followed
by the treatment of desired drugs at indicated concentrations and
time points. Detached cells in culture medium (floating cells) were
collected at indicated times and counted with a hemacytometer.
The attached cells were harvested by trypsinization for counting.
Cell viability of floating and attached cells was also determined by
assessing cellular uptake of trypan blue dye as previously described
[11]. At least three independent experiments were analyzed for
each condition.
Fluorescence Imaging
Phalloidin staining of F-actin and immunofluorescence staining
of p-MLC staining were performed as previously described [11].
To detect ROS in live cells, CM-H2DCFDA (C-6827, Life
Technologies) was used as a reliable fluorogenic marker of ROS in
cells, while 49,6-diamidino-2-phenylindole (DAPI) was used for
nucleus staining; both reagents are membrane permeable in live
cells. MEF cells were seeded and attached to gelatin coated glass
coverslips. After treating cells with desired drugs at indicate time
points, CM-H2DCFDA was added to culture medium at a final
concentration of 13 mM, and incubated for 10 min at 37uC. Cells
were then washed three times with pre-warmed phosphate-
buffered saline (PBS). Coverslips were then mounted in with
Vectashield mounting media (H-1200, Vector Laboratories)
containing DAPI. The oxidative stressed and non-stressed cells
were able to be distinguished under fluorescence microscopy
(Leica DM5500B with objectives: HCX PL FUOTAR 20.060.50,
HCX PL FUOTAR 4060.75) equipped with a DFC300FXR2
camera, and images were analyzed with the Leica AF6000
software.
ROS Measurement by Flow Cytometry
After treating MEF cells with desired drugs for indicated time
periods, medium was removed and cells were incubated in PBS for
10 min, followed by 30 min incubation at 37uC in DMEM
without phenol but containing 5 mM of CM-H2DCFDA. The
Figure 7. ROCK2 deletion reduces DOX-induced ROS production and caspase activation. A. Representative images of CM-H2DCFDA
staining of WT and ROCK22/2MEFs treated for 4 h with 3 mM of doxorubicin. Coverslip was mounted with Vector mounting medium containing DAPI
and imaged immediately by fluorescence microscopy. Bar, 50 mm. B. Quantitative analysis of the images obtained from fluorescence microscopy with
the Leica AF6000 software. Fluorescence levels in WT cells at baseline were arbitrarily set at 1, showing reduced doxorubicin-induced ROS production
in ROCK2 deficient cells. C. Representative image of Western blot of ROCK2, cleaved caspase-3, -8, and -9 in cell lysates from attached WT and
ROCK22/2 MEFs treated for 16 h with increasing dosages of doxorubicin as indicated. D. Quantitative analysis of immunoreactive bands of cleaved
capsase-3 (n= 4–6 for each condition), expressed as percent change relative to WT cells treated with doxorubicin, showing reduced caspase
activation in ROCK2 deficient cells treated with 3 or 5 mM doxorubicin. *P,0.05 vs. control of the same genotype. #P,0.05 vs. WT under the same
treatment condition.
doi:10.1371/journal.pone.0090758.g007
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attached cells were collected and suspended in PBS buffer for flow
cytometry analysis. All data were acquired with Becton Dickinson
FACSCalibur and analyzed with CellQuest software. The samples
under the same treatment were prepared in triplicate, and the data
were acquired twice by FACS.
Protein Analysis
Following treatment with desired drugs, attached cells were
harvested and analyzed for caspase activation by Western blot
analysis as previously described [11]. The blots were then probed
with primary antibodies to ROCK1 (GTX61382) from GeneTex,
ROCK2 (sc-5561) from Santa Cruz Biotechnology, p67phox (07-
502) from Millipore, cleaved caspase 3 (#9661), cleaved caspase 9
Figure 8. ROCK2 deletion does not preserve central stress fibers in doxorubicin-treated cells with or without NAC or DPI, and does
not enhance the anti-apoptotic effect of DPI. A. Representative images of rhodamine-phalloidin staining for F-actin (red) and DAPI staining
(blue) of ROCK22/2 cells treated with 3 mM doxorubicin and/or 2 mM NAC or 1 mM DPI for 16 h. Cells showing disruption of central stress fibers are
indicated with white arrowheads. Cells showing folded periphery membranes are indicated with white arrowheads. DPI treatment alone induces
periphery membrane folding in ROCK22/2 cells. Bar, 50 mm. B and C. Floating and attached cells were collected at 16 h post-treatment with 3 mM
doxorubicin and/or 2 mM NAC (B) and/or 1 mM DPI (C). Floating cell ratio was expressed as percentage of total cells (floating plus attached cells)
under each treatment condition. No significant difference was observed between WT and ROCK2 deficient cells under the same treatment condition.
ROCK2 deletion does not enhance the anti-detachment effects of NAC. DPI treatment increases doxorubicin-induced cell detachment in WT and
ROCK2 deficient MEFs. D. Representative image of Western blot of cleaved caspase-3, -8, and -9 in cell lysates from attached WT and ROCK2 deficient
MEFs treated for 16 h with 3 mM doxorubicin and/or 1 mM DPI. E. Densitometry analysis of immunoreactive bands of cleaved caspase-3 expressed as
percent change relative to WT cells treated with 3 mM doxorubicin, showing no further reduction in caspase activation by DPI treatment in
doxorubicin-treated ROCK2 deficient MEFs. *P,0.05 vs. control of the same genotype. #P,0.05 vs. WT under the same treatment condition. "P,0.05
vs. the same genotype under doxorubicin only condition.
doi:10.1371/journal.pone.0090758.g008
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(#9509), cleaved caspase 8 (#9429), PARP (#9542), cofilin
(#3312), p-cofilin(Ser3) (#3311), MLC (#3672), p-MLC(Ser19)
(#3671) from Cell Signaling. After blotting with corresponding
secondary antibodies conjugated with horseradish peroxidase, the
membranes were developed with ECL Western blotting or
SuperSignal West Pico Chemiluminescent Substrate (Thermo
Scientific), and the blots were visualized by using a Fujifilm LAS-
4000 Imager. All blots were normalized to GAPDH (MA5-15738,
Thermo Scientific) or to actin (sc-1616; Santa Cruz Biotechnol-
ogy).
Subcellular Fractionation
To separate cytosolic and membrane fractions, cells were
washed with cold PBS after removing culture medium, solubilized
with Tris lysis buffer (20 mM Tris, pH 7.5, 100 mM NaCl, 5 mM
EDTA plus protease inhibitor and phosphatase inhibitor cocktails
(Roche)). The debris was pelleted at 700 g for 10 minutes, and the
supernatant was further centrifuged at 100,000 g for 60 minutes at
4uC. The supernatant then was saved as the cytosolic fraction and
the pellet was suspended in Tris lysis buffer containing 1% Triton
X-100 as the membrane fraction. Proteins (50 mg) from each
fraction were analyzed by Western blotting as described above.
NADPH Oxidase Activity Assay
NADPH oxidase activity in intact cells was measured using a
modified assay [51]. Briefly, photon emission from the chromo-
genic substrate lucigenin was measured every 15 s for 20 min in
an Lmax Microplate Luminometer (Molecular Devices). Luci-
genin serves as the acceptor of electron/O2
2 generated by the
NADPH oxidase complex. Activity measurement was performed
in a 250-mM HEPES buffer, pH 7.4, containing NaCl 120 mM,
KCl 5.9 mM, MgSO4 1.2 mM, CaCl2 1.75 mM, EDTA 0.5 mM,
glucose 11 mM, lucigenin 0.2 mM, and NADPH 0.1 mM as the
substrate. Non-treated or doxorubicin-treated cells were collected,
counted, and pelleted at 4006g at 4uC for 4 min; the pellet was re-
suspended in a balanced salt solution containing NaCl 130 mM,
KCl 5 mM, MgCl2 1 mM, CaCl2 1.5 mM, phosphoric acid
35 mM, and HEPES 20 mM, pH 7.4. 0.56106 cells in balanced
salt solution containing 10 mM glucose and 1 mg/mL bovine
serum albumin were used in measurement. A buffer blank was
subtracted from each reading before data calculation. No activity
could be measured in the absence of NADPH or in the presence of
100 mM DPI.
Rac1 Activity Assay
Rac1 activation was assessed by Rac1-GTP pull down assay
using PAK-1 PBD-agarose beads (#17–283, Millipore). Cell
lysates (800 mg) were pre-cleared with glutathione agarose beads
(SC-2009, Santa Cruz)) at 4uC for 10 min. The supernatant was
then incubated with PAK-1 PBD-agarose beads at 4uC for 1 h.
The beads were then washed 3 times with the lysis buffer and
followed by boiling in Laemmli reducing sample buffer to release
active Rac1, which was detected with anti-Rac1 mouse monoclo-
nal 23A8 (05–389, Millipore) by Western blotting.
Statistical Analysis
Data are reported as mean 6 SE. Comparisons between
groups were analyzed by Student’s t-test or ANOVA as appropriate,
with P,0.05 considered as significant.
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Figure 9. Schematic summary. The diagram summarizes the effects of anti-oxidants (NAC and DPI) and ROCK1 deficiency in opposing ROS
production, apoptosis, actin cytoskeleton reorganization, and cell detachment induced by doxorubicin. NAC reduces ROS production leading to
reduced apoptosis. NAC also decreases actin cytoskeleton remodeling in part through decreasing MLC phosphorylation and actomyosin contraction
leading to reduced cell detachment. However, NAC inhibits actin polymerization through reducing cofilin phosphorylation, and therefore does not
prevent the disruption of central stress fibers. DPI reduces ROS production and apoptosis, supporting a contributory role in doxorubicin-induced ROS
production. ROCK1 deficiency reduces ROS production, in part through inhibiting NADPH oxidase activation. Finally, ROCK1 deficiency presents a
unique property of preserving central stress fiber stability through reducing MLC phosphorylation and preserving cofilin phosphorylation, leading to
the preserved cell adhesion which then enhances the protective effects of antioxidant treatment against doxorubicin-induced ROS production,
apoptosis and cell detachment.
doi:10.1371/journal.pone.0090758.g009
ROCK Isoform Function in Oxidative Stress Response
PLOS ONE | www.plosone.org 11 March 2014 | Volume 9 | Issue 3 | e90758
References
1. Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, et al. (1996) Rho-
associated kinase, a novel serine/threonine kinase, as a putative target for small
GTP binding protein Rho. Embo J 15: 2208–2216.
2. Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, et al. (1996) The
small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr
protein kinase homologous to myotonic dystrophy kinase. Embo J 15: 1885–
1893.
3. Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, et al. (1996) ROCK-I
and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein
serine/threonine kinase in mice. FEBS Lett 392: 189–193.
4. Amano M, Fukata Y, Kaibuchi K (2000) Regulation and functions of Rho-
associated kinase. Exp Cell Res 261: 44–51.
5. Riento K, Ridley AJ (2003) Rocks: multifunctional kinases in cell behaviour. Nat
Rev Mol Cell Biol 4: 446–456.
6. Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, et al. (1997)
Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase.
Science 275: 1308–1311.
7. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, et al. (1996) Regulation of
myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science
273: 245–248.
8. Leung T, Chen XQ, Manser E, Lim L (1996) The p160 RhoA-binding kinase
ROK alpha is a member of a kinase family and is involved in the reorganization
of the cytoskeleton. Mol Cell Biol 16: 5313–5327.
9. Maekawa M, Ishizaki T, Boku S, Watanabe N, Fujita A, et al. (1999) Signaling
from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-
kinase. Science 285: 895–898.
10. Arber S, Barbayannis FA, Hanser H, Schneider C, Stanyon CA, et al. (1998)
Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase.
Nature 393: 805–809.
11. Shi J, Wu X, Surma M, Vemula S, Zhang L, et al. (2013) Distinct roles for
ROCK1 and ROCK2 in the regulation of cell detachment. Cell Death Dis 4:
e483.
12. Shi J, Surma M, Zhang L, Wei L (2013) Dissecting the roles of ROCK isoforms
in stress-induced cell detachment. Cell Cycle 12: 1492–1500.
13. Feng Z, Chen B, Tang SC, Liao K, Chen WN, et al. (2010) Effect of
cytoskeleton inhibitors on deadhesion kinetics of HepG2 cells on biomimetic
surface. Colloids Surf B Biointerfaces 75: 67–74.
14. Colombo R, Dalle Donne I, Milzani A (1990) Metal ions modulate the effect of
doxorubicin on actin assembly. Cancer Biochem Biophys 11: 217–226.
15. Doroshow JH, Davies KJ (1986) Redox cycling of anthracyclines by cardiac
mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and
hydroxyl radical. J Biol Chem 261: 3068–3074.
16. Rajagopalan S, Politi PM, Sinha BK, Myers CE (1988) Adriamycin-induced free
radical formation in the perfused rat heart: implications for cardiotoxicity.
Cancer Res 48: 4766–4769.
17. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C (2002)
Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte
apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase
activity, and Bcl-2:Bax ratio. Cancer Res 62: 4592–4598.
18. Kotamraju S, Konorev EA, Joseph J, Kalyanaraman B (2000) Doxorubicin-
induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by
nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species.
J Biol Chem 275: 33585–33592.
19. Shi J, Zhang L, Zhang YW, Surma M, Mark Payne R, et al. (2012)
Downregulation of doxorubicin-induced myocardial apoptosis accompanies
postnatal heart maturation. Am J Physiol Heart Circ Physiol 302: H1603–1613.
20. Shi J, Abdelwahid E, Wei L (2011) Apoptosis in Anthracycline Cardiomyopathy.
Curr Pediatr Rev 7: 329–336.
21. Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC (2010) Mechanisms of
anthracycline cardiac injury: can we identify strategies for cardioprotection?
Prog Cardiovasc Dis 53: 105–113.
22. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, et al. (2012)
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to thera-
peutic strategies. J Mol Cell Cardiol 52: 1213–1225.
23. Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy.
N Engl J Med 339: 900–905.
24. Yeh ET, Bickford CL (2009) Cardiovascular complications of cancer therapy:
incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53:
2231–2247.
25. Tacar O, Sriamornsak P, Dass CR (2013) Doxorubicin: an update on anticancer
molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol
65: 157–170.
26. Zhang YW, Shi J, Li YJ, Wei L (2009) Cardiomyocyte death in doxorubicin-
induced cardiotoxicity. Arch Immunol Ther Exp (Warsz) 57: 435–445.
27. Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, et al. (2009)
Anthracycline-induced cardiotoxicity: overview of studies examining the roles of
oxidative stress and free cellular iron. Pharmacol Rep 61: 154–171.
28. van Dalen EC, Caron HN, Dickinson HO, Kremer LC (2011) Cardioprotective
interventions for cancer patients receiving anthracyclines. Cochrane Database
Syst Rev: CD003917.
29. Millea PJ (2009) N-acetylcysteine: multiple clinical applications. Am Fam
Physician 80: 265–269.
30. Samuni Y, Goldstein S, Dean OM, Berk M (2013) The chemistry and biological
activities of N-acetylcysteine. Biochim Biophys Acta 1830: 4117–4129.
31. Doroshow JH, Locker GY, Ifrim I, Myers CE (1981) Prevention of doxorubicin
cardiac toxicity in the mouse by N-acetylcysteine. J Clin Invest 68: 1053–1064.
32. Deng S, Kruger A, Kleschyov AL, Kalinowski L, Daiber A, et al. (2007)
Gp91phox-containing NAD(P)H oxidase increases superoxide formation by
doxorubicin and NADPH. Free Radic Biol Med 42: 466–473.
33. Zhao Y, McLaughlin D, Robinson E, Harvey AP, Hookham MB, et al. (2010)
Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with
Doxorubicin chemotherapy. Cancer Res 70: 9287–9297.
34. Brandes RP, Kreuzer J (2005) Vascular NADPH oxidases: molecular
mechanisms of activation. Cardiovasc Res 65: 16–27.
35. Nisimoto Y, Freeman JL, Motalebi SA, Hirshberg M, Lambeth JD (1997) Rac
binding to p67(phox). Structural basis for interactions of the Rac1 effector region
and insert region with components of the respiratory burst oxidase. J Biol Chem
272: 18834–18841.
36. Gorzalczany Y, Sigal N, Itan M, Lotan O, Pick E (2000) Targeting of Rac1 to
the phagocyte membrane is sufficient for the induction of NADPH oxidase
assembly. J Biol Chem 275: 40073–40081.
37. Moon C, Lee YJ, Park HJ, Chong YH, Kang JL (2010) N-acetylcysteine inhibits
RhoA and promotes apoptotic cell clearance during intense lung inflammation.
Am J Respir Crit Care Med 181: 374–387.
38. Aghajanian A, Wittchen ES, Campbell SL, Burridge K (2009) Direct activation
of RhoA by reactive oxygen species requires a redox-sensitive motif. PLoS One
4: e8045.
39. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, et al. (2003) Long-term
inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular
hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system.
Circ Res 93: 767–775.
40. Shiotani S, Shimada M, Taketomi A, Soejima Y, Yoshizumi T, et al. (2007)
Rho-kinase as a novel gene therapeutic target in treatment of cold ischemia/
reperfusion-induced acute lethal liver injury: effect on hepatocellular NADPH
oxidase system. Gene Ther 14: 1425–1433.
41. Lemarie A, Bourdonnay E, Morzadec C, Fardel O, Vernhet L (2008) Inorganic
arsenic activates reduced NADPH oxidase in human primary macrophages
through a Rho kinase/p38 kinase pathway. J Immunol 180: 6010–6017.
42. Mali RS, Ramdas B, Ma P, Shi J, Munugalavadla V, et al. (2011) Rho kinase
regulates the survival and transformation of cells bearing oncogenic forms of
KIT, FLT3, and BCR-ABL. Cancer Cell 20: 357–369.
43. Hahmann C, Schroeter T (2010) Rho-kinase inhibitors as therapeutics: from pan
inhibition to isoform selectivity. Cell Mol Life Sci 67: 171–177.
44. Surma M, Wei L, Shi J (2011) Rho kinase as a therapeutic target in
cardiovascular disease. Future Cardiol 7: 657–671.
45. Rath N, Olson MF (2012) Rho-associated kinases in tumorigenesis: re-
considering ROCK inhibition for cancer therapy. EMBO Rep 13: 900–908.
46. Shi J, Wei L (2013) Rho Kinases in Cardiovascular Physiology and
Pathophysiology: The Effect of Fasudil. J Cardiovasc Pharmacol 62: 341–354.
47. Wang N, Guan P, Zhang JP, Chang YZ, Gu LJ, et al. (2011) Preventive effects of
fasudil on adriamycin-induced cardiomyopathy: possible involvement of
inhibition of RhoA/ROCK pathway. Food Chem Toxicol 49: 2975–2982.
48. Zhang YM, Bo J, Taffet GE, Chang J, Shi J, et al. (2006) Targeted deletion of
ROCK1 protects the heart against pressure overload by inhibiting reactive
fibrosis. FASEB J. 20: 916–925.
49. Chang J, Xie M, Shah VR, Schneider MD, Entman ML, et al. (2006) Activation
of Rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage
plays an essential role in cardiac myocyte apoptosis. Proc Natl Acad Sci U S A.
103: 14495–14500.
50. Shi J, Zhang YW, Yang Y, Zhang L, Wei L.(2010) ROCK1 plays an essential
role in the transition from cardiac hypertrophy to failure in mice. J Mol Cell
Cardiol. 49: 819–828.
51. Abid MR, Spokes KC, Shih SC, Aird WC (2007) NADPH oxidase activity
selectively modulates vascular endothelial growth factor signaling pathways.
J Biol Chem 282: 35373–35385.
ROCK Isoform Function in Oxidative Stress Response
PLOS ONE | www.plosone.org 12 March 2014 | Volume 9 | Issue 3 | e90758
